<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044772</url>
  </required_header>
  <id_info>
    <org_study_id>0600B5-399</org_study_id>
    <nct_id>NCT00044772</nct_id>
  </id_info>
  <brief_title>Study Evaluating Venlafaxine ER in Patients With Panic Disorder</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine&#xD;
      extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in&#xD;
      comparison to those of placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">653</enrollment>
  <condition>Panic Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine ER</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before&#xD;
             study day 1&#xD;
&#xD;
          -  Have sufficient symptoms to require anxiolytic drug therapy&#xD;
&#xD;
          -  Have a score â‰¥4 on the Clinical Global Impressions Scale (CGI) severity of illness&#xD;
             item at screening and baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine&#xD;
&#xD;
          -  History or presence of any clinically important hepatic, renal, or other medical&#xD;
             disease that might compromise the study or be detrimental to the patient (eg,&#xD;
             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal&#xD;
             cell epithelioma], uncontrolled hypertension)&#xD;
&#xD;
          -  Clinically important abnormality on screening physical examination, vital signs,&#xD;
             electrocardiogram (ECG), laboratory tests or urine drug screen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>September 4, 2002</study_first_submitted>
  <study_first_submitted_qc>September 5, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2002</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <keyword>Panic</keyword>
  <keyword>Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

